| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA769: Palforzia for treating peanut allergy in children and young people |
|
Medicine details |
|
| Medicine name | arachis hypogaea (AR101) (Palforzia®) |
| Formulation | 0.5 mg, 1 mg, 10 mg, 20 mg, 100 mg, 300 mg oral powder |
| Reference number | 3134 |
| Indication | Treatment of patients aged 4 to 17 years with confirmed diagnosis of peanut allergy. Palforzia may be continued in patients 18 years and older |
| Company | Aimmune Therapeutics |
| BNF chapter | Respiratory system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/04/2021 |
| NICE guidance | TA769: Palforzia for treating peanut allergy in children and young people |